$678.15 Million in Sales Expected for Charles River Laboratories Intl. Inc (NYSE:CRL) This Quarter

Analysts expect Charles River Laboratories Intl. Inc (NYSE:CRL) to report sales of $678.15 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Charles River Laboratories Intl.’s earnings. The highest sales estimate is $681.20 million and the lowest is $675.10 million. Charles River Laboratories Intl. reported sales of $585.30 million during the same quarter last year, which indicates a positive year-over-year growth rate of 15.9%. The company is scheduled to issue its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Charles River Laboratories Intl. will report full year sales of $2.64 billion for the current year, with estimates ranging from $2.63 billion to $2.67 billion. For the next fiscal year, analysts expect that the company will report sales of $2.90 billion, with estimates ranging from $2.87 billion to $2.92 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.08. The company had revenue of $657.60 million for the quarter, compared to analyst estimates of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. Charles River Laboratories Intl.’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.62 earnings per share.

A number of equities research analysts have recently issued reports on the company. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Svb Leerink assumed coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating and a $155.00 target price on the stock. Leerink Swann began coverage on Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating on the stock. Finally, Zacks Investment Research downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday, September 9th. Seven research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $147.62.

Shares of Charles River Laboratories Intl. stock traded up $0.46 on Tuesday, reaching $132.25. 496,775 shares of the company were exchanged, compared to its average volume of 252,224. The stock has a fifty day moving average price of $131.81 and a 200-day moving average price of $136.21. The firm has a market capitalization of $6.43 billion, a price-to-earnings ratio of 21.93, a price-to-earnings-growth ratio of 1.68 and a beta of 1.09. The company has a current ratio of 1.59, a quick ratio of 1.38 and a debt-to-equity ratio of 1.47. Charles River Laboratories Intl. has a fifty-two week low of $103.00 and a fifty-two week high of $149.07.

In other news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction on Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the transaction, the insider now owns 19,327 shares in the company, valued at $2,519,467.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.80% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Atria Investments LLC grew its holdings in shares of Charles River Laboratories Intl. by 36.3% during the second quarter. Atria Investments LLC now owns 4,416 shares of the medical research company’s stock valued at $564,000 after buying an additional 1,176 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Charles River Laboratories Intl. by 1.6% during the 2nd quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock worth $661,344,000 after acquiring an additional 72,827 shares in the last quarter. Vestmark Advisory Solutions Inc. boosted its stake in shares of Charles River Laboratories Intl. by 6.8% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 4,985 shares of the medical research company’s stock worth $707,000 after acquiring an additional 319 shares in the last quarter. Chartwell Investment Partners LLC bought a new stake in shares of Charles River Laboratories Intl. during the 2nd quarter worth about $1,687,000. Finally, Kayne Anderson Rudnick Investment Management LLC boosted its stake in shares of Charles River Laboratories Intl. by 32.5% during the 2nd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 457,776 shares of the medical research company’s stock worth $64,958,000 after acquiring an additional 112,229 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Options Trading – What is a Straddle?

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.